Quantcast
Last updated on April 19, 2014 at 7:46 EDT

Latest Bronchial hyperresponsiveness Stories

2013-05-10 23:20:12

St. Elizabeth Health Center is one of the first hospitals in the nation to offer Bronchial Thermoplasty, a procedure to help patients with severe asthma breathe easier and gain long-lasting control over their asthma. Youngstown, OH (PRWEB) May 10, 2013 St. Elizabeth Health Center is among the first in the United States to offer a new procedure for severe asthma patients, known as bronchial thermoplasty. Patients who are 18 years and older and suffer from severe persistent asthma that is not...

2012-01-03 11:56:00

EXTON, Pa., Jan. 3, 2012 /PRNewswire/ -- Pharmaxis, Inc. today announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a product-specific billing code, or J-code, for ARIDOL® (mannitol inhalation powder) Bronchial Challenge Test Kit. The unique, product-specific billing code, J7665 (mannitol, administered through an inhaler, 5 mg), became effective on January 1, 2012. (Photo: http://photos.prnewswire.com/prnh/20111107/NY00591 ) ARIDOL, the only dry powder...

2011-11-07 08:00:00

EXTON, Pa., Nov. 7, 2011 /PRNewswire/ -- Pharmaxis, Inc. today announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a unique, Level II Health Care Common Procedural Coding System (Level II HCPCS), commonly referred to as a J-code, to ARIDOL® (mannitol inhalation powder) Bronchial Challenge Test Kit, which is used to assess bronchial hyperresponsiveness in patients six years of age and older who do not have clinically apparent asthma. ARIDOL...

2011-09-26 15:08:17

Patients suffering from chronic obstructive pulmonary disease (COPD) are at a higher risk of death if they are underweight. A new study, which will be presented today (26 September 2011) at the European Respiratory Society's Annual Congress in Amsterdam, assessed the link between death rates and the weight of COPD patients. The research also assessed the link with other co-existing diseases, such as heart disease. The World Health Organization predicts that COPD will become the third...

2011-02-23 15:20:00

EXTON, Pa., Feb. 23, 2011 /PRNewswire/ -- Pharmaxis, a global specialty pharmaceutical company focused on therapeutic products for chronic respiratory and immune disorders, announced today the commercial launch of ARIDOL® (mannitol inhalation powder) Bronchial Challenge Test Kit, the first new bronchial challenge test in more than two decades and the company's first product launch in the U.S. ARIDOL is used to assess bronchial hyperresponsiveness in patients six years...

2010-11-10 16:31:00

EXTON, Pa., Nov. 10, 2010 /PRNewswire/ -- Pharmaxis, a global specialty pharmaceutical company focused on therapeutic products for respiratory and immune disorders, will present ARIDOL(TM) (mannitol inhalation powder) Bronchial Challenge Test Kit, at the 2010 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI), November 11-16 in Phoenix, AZ. Approved by the U.S. Food and Drug Administration (FDA) on October 5, 2010, ARIDOL is the first new bronchial...

2010-10-06 12:13:00

EXTON, Pa., Oct. 6 /PRNewswire/ -- Pharmaxis, a global specialty pharmaceutical company focused on therapeutic products for chronic respiratory and immune disorders, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market ARIDOL(TM) (mannitol inhalation powder) Bronchial Challenge Test Kit, the first new bronchial challenge test in more than two decades. ARIDOL is used for the assessment of bronchial hyperresponsiveness in patients six...

edb24ce851d3bdd1cefc61a040110a311
2010-06-17 12:40:00

New research has found that kids who grow up with a dog in the house may be at a higher risk of developing asthma if they are also exposed to secondhand smoke or nitrogen dioxide. Children exposed to these elements were about fives times as likely to have asthma at age 7 than kids who had neither exposure.  Dr. Chris Carlsten of Vancouver General Hospital in British Columbia, Canada and colleagues point out in the European Respiratory Journal that most studies in children have looked...

2009-03-11 01:10:00

SYDNEY, March 11 /PRNewswire-Asia/ -- Pharmaxis (ASX: PXS; NASDAQ: PXSL) is pleased to announce that it has appointed Praxis Pharmaceutical France SARL as its French marketer and distributer for the asthma diagnostic tool, Aridol. Praxis Pharmaceutical is a recently established company created to introduce a portfolio of respiratory specialist products into the French pharmaceutical market. Praxis will complete the reimbursement application for Aridol in France and thereafter market...

2009-03-03 08:14:00

A Potential New Tool in the Diagnosis and Assessment of Asthma EXTON, Pa., March 3 /PRNewswire/ -- Pharmaxis, Inc., a wholly owned subsidiary of Pharmaxis Ltd (ASX: PXS, Nasdaq: PXSL), an emerging respiratory specialty pharmaceutical company, announced today that it has filed a New Drug Application (NDA), electronically, with the U.S. Food and Drug Administration (FDA) for Aridol(TM) (mannitol bronchial challenge test). Bronchial challenge tests are designed to assess bronchial...